Pfizer shares up 3.05%, after oversold signals attract buyer interest

Traders Union
All News
Financial News
Pfizer rises 3.05% today on gains

Highlights

Pfizer's third-quarter earnings per share declined year-over-year from $0.78 to $0.62, reflecting weaker operational performance.
The company maintains an attractive quarterly dividend of $0.43 per share, offering a 6.9% yield despite current investor caution.
Pfizer plans to raise $5 billion to fund its acquisition of Metsera, having secured the deal over another competing bidder.

Cautious sentiment persists as earnings slide and acquisition plans emerge

Pfizer reported a year-over-year decline in third-quarter earnings, with earnings per share falling to $0.62 from $0.78. The company continues to offer an attractive quarterly dividend of $0.43 per share, representing a 6.9% yield, but investor sentiment remains cautious. Additionally, Pfizer disclosed plans to raise $5 billion to finance the acquisition of Metsera after securing the deal over another bidder.

Technical bias constructive as resistance challenges and mixed momentum shape outlook

Technically, PFE is trading above its MA-20, MA-50, and MA-200, highlighting a constructive short- and medium-term bias with long-term support remaining intact. The closest resistance is the Ichimoku Kijun at $25.20, while the MA-50 offers dynamic support just below current levels. Momentum indicators are mixed: the daily MACD signals strong buy, yet ADX is neutral and offers limited conviction. RSI faces slight downside, with Stoch RSI and Bull/Bear Power (BBP) both indicating oversold conditions where buyer interest has recently improved; CCI and the Awesome Oscillator register as neutral.

Neutral trend likely as price faces tight range and direction risk

In the short term, Pfizer is expected to move within a range of $24.60–$25.40. A breakout above $25.20 and sustained consolidation is needed to turn momentum decisively bullish. If the price drops below dynamic support near $24.60, downside risk may accelerate. Sideways consolidation above $24.80–$25.20 remains the most likely scenario as weekly trend indicators lean neutral to bearish.

Viktoras Karapetjanc, expert at Traders Union, sees Pfizer’s technical resilience as a positive signal despite soft quarterly earnings. He believes the ongoing dividend appeal and recent acquisition news have improved sentiment. However, the analyst notes that sustained upside must clear resistance at $25.20 to confirm a bullish shift. Momentum remains constructive with intact long-term support levels. "If Pfizer consolidates above $25.20 and maintains its fundamental strength, I expect the stock to attract further buyer interest," he says.

Previously it was noted that Pfizer remained above its key moving averages, with technical indicators suggesting mixed momentum as overbought signals clashed with trend support. Investors were closely following whether recent acquisitions and agreements would help the stock recover from recent underperformance.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.